Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Feng WenHanrui ZhengPengfei ZhangWeiting LiaoKexun ZhouQiu LiPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
The combination of atezolizumab and bevacizumab was not a cost-effective strategy for the first-line systemic treatment of unresectable HCC from the Chinese and American payers' perspective.